NEW YORK ( F.A.S.T. Graphs) -- Affordable health care is a huge problem for America, and the jury is still out on whether the Affordable Healthcare Act, aka, Obamacare is a blessing or curse.
Based on fundamentals, AmSurg Corp is very attractively priced today. The following earnings and price correlated F.A.S.T. Graphs (the orange line plots earnings, the black line price), reveals the stock is currently trading at a low valuation relative to its historical norms.
Price to sales is another important measurement of valuation. Currently, AmSurg can be bought at a price to sales of 1.12, which is approximately half the historically normal price to sales ratio. Even though AmSurg is trading at a historically low valuation, thanks to its strong record of earnings growth, it has handily outperformed the S&P 500 since 1998. A $1,000 investment on December 31, 1998, would have grown to $6,630.51. This represents a 14.2% compound annual rate of return, which highly correlates to the company's long-term earnings growth rate of 16.1%, adjusted by today's low valuation. The consensus of eight analysts reporting to Standard & Poor's Capital IQ, expect AmSurg's earnings to grow at over 13.5% for the next five years. This above-average forecast growth is consistent with the realities of the state of health care in America today. Thesis for Growth The following company profile taken directly from the company's 2011 annual report summarizes AmSurg's business. The key phrase in the profile is "low-cost surgery services." Reducing health care costs is a huge plus in this demographically rich business opportunity.
AmSurg acquires, develops and operates ambulatory surgery centers in partnership with physicians. Headquartered in Nashville, Tenn., AmSurg operated 228 ambulatory surgery centers at Dec. 31, 2011. By focusing on the delivery of high-quality, low-cost surgery services that create high patient and physician satisfaction, AmSurg creates value for the three constituencies involved in every surgical procedure: the patient, the physician and the payor.According to Christopher A. Holden, president, CEO and director, speaking to the Barclays Global Healthcare Conference on March 13, health-care reform is a net positive for the company's long-term growth and profitability. He reported that over the last three decades there's been a paradigm shift where the vast majority of all surgery is performed on an outpatient basis.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts